Your browser is out of date

With an updated browser, you will have a better Medtronic website experience. Update my browser now.

×

Skip to main content


Transcatheter
Aortic Valve
Implantation (TAVI)

TAVI – Returning faster to an active life


Aortic stenosis is the most common valvular heart disease in Europe.1

With TAVI, the stenosed aortic valve can be treated in a fast and safe way thanks to a catheter-based treatment.

The procedure time and hospital stay are typically short, allowing patients to return faster home and being active again.2,3

Tavi valve illustration image
Old couple hugging each other

Symptomatic
aortic stenosis

Timing is everything
Review data on the urgency to treat aortic stenosis and discover useful materials to support you.

Family walking

Diagnosis and patient evaluation

For treatment with TAVI
Find information to identify patients who benefit from TAVI according to the ESC/EACTS AS guidelines.

Couple dancing together

About the TAVI  therapy

A minimally invasive alternative
Watch the TAVI procedure animation to learn more about the therapy for easy patient conversations.

Female doc showing phone to patient

Patient resources
aortic stenosis

About aortic stenosis and
treatment options

Request patient materials and find local heart valve patient organisations to share with your patients.
 

Group of hcp professionals

2021 ESC/EACTS VHD guidelines

Summary and
key considerations
Discover our summary of the latest ESC/EACTS aortic stenosis guidelines and supporting materials for you.
 

Tavi illustration

Detecting LF/LG aortic stenosis

Echo-guide and steps to assess AS severity
Identify low-flow, low-gradient aortic stenosis criteria from the ESC/EACTS guidelines and overcome pitfalls in AS detection.

Download
Aortic Stenosis
Evolut™ TAVI App

1

Carabello BA, Paulus WJ. Aortic stenosis. Lancet. March 14, 2009;373(9667):956-966.

2

Reardon MJ. Deep Dive From the Evolut Low Risk Trial. Presented at ACC 2019; New Orleans, LA.

3

Modine T. The impact of procedural complications on recovery and quality of life after TAVI or SAVR in patients at low risk of mortality following surgery. Presented at EuroPCR 2019; Paris, France. 

See the CoreValve™ Evolut™ R, the CoreValve™ Evolut™PRO and the Evolut™ PRO+ device manuals for detailed information regarding the instructions for use, the implant procedure, indications, contraindications, warnings, precautions, and potential adverse events. For further information, contact your local Medtronic representative and/or consult the Medtronic website at medtronic.eu.

For applicable products, consult instructions for use at www.medtronic.com/manuals. Manuals can be viewed using a current version of any major internet browser. For best results, use Adobe Acrobat® Reader with the browser.

The commercial name of the Evolut™ R device is Medtronic CoreValve™ Evolut™ R System, the commercial name of the Evolut™ PRO device is Medtronic CoreValve™ Evolut™ PRO System, and the commercial name of the Evolut™ PRO+ device is Medtronic Evolut™ PRO+ System.

© 2020 Medtronic. All rights reserved, Medtronic, Medtronic logo and Further, Together are trademarks of Medtronic™.* Third party brands are trademarks of their respective owners. All other brands are trademarks of a Medtronic company.